Key Highlights
- CMS proposed the CRUSH rule on Monday, November 16.
- The rule would expand audits of Medicare Advantage payments.
- UnitedHealth and Humana led the insurer slide.
- CRUSH stands for Comprehensive Regulations to Uncover Suspicious Healthcare.
The rule in brief
The Centers for Medicare & Medicaid Services, the federal agency that runs Medicare, has proposed a rule with an attention-grabbing name: "Comprehensive Regulations to Uncover Suspicious Healthcare," or CRUSH. Released on Monday, November 16, the proposal targets payments to Medicare Advantage plans, the privately run alternative to traditional Medicare offered by insurers such as UnitedHealth Group (NYSE:UNH), Humana (NYSE:HUM) and Elevance Health (NYSE:ELV).
At its core, the rule would change how the government audits those payments. Under what are known as risk adjustment data validation, or RADV, audits, CMS reviews a sample of patient records to check whether the diagnoses insurers reported, which drive how much the plans are paid, are supported by medical documentation. The proposal would allow CMS to extrapolate audit findings from a sample to an entire contract, and it would extend the audit and overpayment lookback to payment year 2018.
CMS says the rule could save about $90 billion over 10 years. CMS estimates the impact at about $9 billion per payment year. The rule is not final, and public comments are due January 19, 2027.
A familiar fight
The proposal revives a 2023 RADV rule that a federal judge in Texas vacated in September 2025 in a case brought by Humana. CMS Administrator Dr. Mehmet Oz framed the new effort as a way to "crush fraud, waste, and abuse."
Oppenheimer expects legal challenges, and thinks plans would price the cost into their bids. One analyst said: "The substantially larger collection estimate reflects broader auditing." He added that CMS "could choose to make adjustments in the final rule."
Why the stocks fell
Investors reacted to the potential for large repayments and lower future profits from Medicare Advantage, a major Business line for many insurers. UnitedHealth tumbled and was the worst performer in the Dow Jones Industrial Average. Humana plunged and was the worst performer in the S&P 500. Elevance Health, Centene (NYSE:CNC) and CVS Health (NYSE:CVS) also sank, while Cigna (NYSE:CI), Molina Healthcare (NYSE:MOH) and Oscar Health (NYSE:OSCR) fell as well. It was the second straight day of declines for the group.
Humana is especially exposed. Medicare Advantage accounted for $99.4 billion of its $129.7 billion in 2025 revenue.
The selling spilled into the broader market. Health care was among the weakest sectors in the S&P 500, second only to energy, and the sector's slide pushed the Dow to its session low. The Dow closed down 561.25 points at 50,198.17, with UnitedHealth the biggest drag. The S&P 500 slipped 16.90 points to 7,323.63, its fifth straight loss.
Political crosscurrents
The insurers were already facing scrutiny from Washington. Sen. Elizabeth Warren wrote on X that UnitedHealth, CVS and Cigna "each own a health insurer, pharmacy middleman, and pharmacy" and "take a cut at every step."
Medicare Advantage Audits Redraw the Risk for Insurers
The comment period, which runs until January 19, 2027, is the next milestone, giving insurers and industry groups a chance to weigh in. Investors will watch whether CMS changes the proposal in its final version, as Wiederhorn noted it could, and whether any legal challenge is filed. UnitedHealth is due to give its 2027 outlook before year-end, which could show how management is factoring in the proposal. Medicare Advantage bids for future years will also reveal how plans respond.






Please wait processing your request...